Subscribe to Newsletter

Business & Regulation

Business & Regulation Standards & Regulation

Saying Farewell to the Famous Horse Tweet

| Stephanie Vine | 5 min read

Why the FDA must delete its statement that people are not horses (or cows), referring to ivermectin use

Business & Regulation Standards & Regulation

FDA Warning Letters: April 2024 Edition

| Stephanie Vine | 6 min read

Production records written using erasable markers, use of expired raw materials, and more.

Business & Regulation Technology and Equipment

Interphex: The Finale

| Stephanie Vine | 2 min read

Day 3 closes out with sessions on drug delivery devices

Business & Regulation Technology and Equipment

Day 2 of Interphex

| Stephanie Vine | 2 min read

Looking for a guide to day 2 of the show? We’ve got you covered.

Business & Regulation Technology and Equipment

Welcome to Interphex 2024!

| Stephanie Vine | 3 min read

Interphex kicks off today in New York. Here’s what to look out for on day 1.

Business & Regulation Business Practice

Video Interview: The High Costs of Advanced Therapies, Part 2

| Stephanie Vine

Cardinal Health’s Fran Gregory looks at innovative payment models for cell and gene therapies.

Business & Regulation Business Practice

Video Interview: The High Costs of Advanced Therapies, Part 1

| Stephanie Vine

Cardinal Health’s Fran Gregory talks about the high costs of cell and gene therapies, and what this means for payers.

Business & Regulation Profession

Talent Spotting in Pharma

| Stephanie Vine | 5 min read

Have you noticed a shortage of skilled individuals entering the pharma industry?

Business & Regulation Standards & Regulation

Showdown Over the Abortion Pill in the US

| Stephanie Vine | 4 min read

The Supreme Court will decide the fate of the abortion pill mifepristone in the US on March 26, 2024.

Business & Regulation Business Practice

Drug Price Negotiations, Counteroffers, and Lawsuits

| Stephanie Vine | 4 min read

The US Inflation Reduction Act continues to generate controversy as drugmakers make counteroffers.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register